GlassScriptPhysician profile
Alexis C Smith
NPI 1235428103
$725,902.29
in general payments reported to CMS, 2019-2025
15 companies · $234K in 2025
The $234K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $13K · 2021: $51K · 2022: $153K · 2023: $149K · 2024: $126K · 2025: $234K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $393K · Consulting Fee: $63K · Travel and Lodging: $38K · Food and Beverage: $11K · Education: $4,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $392,922.00 |
| Consulting Fee | $63,156.50 |
| Travel and Lodging | $37,968.46 |
| Food and Beverage | $10,770.01 |
| Education | $4,046.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391,137.71 | 2019-2025 | Nucala, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $277,220.50 | 2020-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $27,534.77 | 2019-2025 | |
| Amgen INC. | $25,061.82 | 2022-2023 | Tezspire |
| Intuitive Surgical, INC. | $4,403.99 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $252.13 | 2019-2020 | |
| Insmed, INC. | $74.10 | 2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $64.58 | 2023 | Dupixent |
| Mylan Specialty L.P. | $32.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.11 | 2021-2022 | |
| United Therapeutics Corporation | $22.10 | 2025 | Tyvaso |
| Siemens Medical Solutions USA, INC. | $19.22 | 2025 | Somatom Pro.Pulse |
| Phadia US INC. | $18.96 | 2023 | Immunocap |
| Baxter Healthcare | $16.13 | 2022 | |
| Boston Scientific Corporation | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.